21 Sep 2018 12:56
For immediate release | 21 September 2018 |
ABCAM PLC
(the 'Company')
Publication of 2018 Annual Report and Accounts
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that its Annual Report and Accounts for the year ended 30 June 2018 will be published today on the Company's investor relations website, www.abcamplc.com.
It will also be posted today, together with the Notice of Annual General Meeting, to those shareholders that have elected to receive paper communications. Shareholders that have not elected to receive paper communications will be notified of the availability of these documents on the Company's investor relations website, www.abcamplc.com.
For further information please contact:
Abcam plc | + 44 (0) 1223 696 000 |
Suzanne Smith, Company Secretary James Staveley, Vice President Investor Relations
| |
J.P.Morgan Cazenove - Nominated Advisor & Corporate Broker | + 44 (0) 20 7742 4000 |
James Mitford / Jonty Edwards | |
FTI Consulting | + 44 (0) 20 3727 1000 |
About Abcam plc
As an innovator of reagents and tools, Abcam's purpose is to serve life scientists globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Group offers highly validated biological binders and assays to address important targets in critical biological pathways.
A pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's antibodies and affinity binders, reagents, biomarkers and assays and the Group's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.
By actively listening to and collaborating with researchers, the Group continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.
Abcam's eleven locations are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Group sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).
To discover more, please visit www.abcam.com and www.abcamplc.com